1592003-24-1

Basic information

• Product Name: 5-(2-hydroxy-4-methoxybenzoyl)-1-(2-hydroxyethyl)pyridin-2(1H)-one
• Synonyms: 5-(2-hydroxy-4-methoxybenzoyl)-1-(2-hydroxyethyl)pyridin-2(1H)-one
• CAS NO: 1592003-24-1
• Molecular Weight: 289.288
• Mol File: 1592003-24-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-(2-hydroxy-4-methoxybenzoyl)-1-(2-hydroxyethyl)pyridin-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(2-hydroxy-4-methoxybenzoyl)-1-(2-hydroxyethyl)pyridin-2(1H)-one(1592003-24-1)
• EPA Substance Registry System: 5-(2-hydroxy-4-methoxybenzoyl)-1-(2-hydroxyethyl)pyridin-2(1H)-one(1592003-24-1)

Safety Data

• Hazardous Substances Data: 1592003-24-1(Hazardous Substances Data)

Upstream product

• 55593-64-1 C₁₂H₈O₅ 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 42059-48-3 acetic acid 4-acetyl-3-hydroxyphenyl ester 
• 42059-49-4 7-Acetoxychromone-3-carboxaldehyde 
• 1402155-26-3 ethyl (2E)-3-(7-methoxy-4-oxo-4H-1-benzopyran-3-yl)acrylate 
• 141-43-5 ethanolamine 

Relevant articles and documents

Synthesis and evaluation of c-Src kinase inhibitory activity of pyridin-2(1H)-one derivatives

Src kinase, a prototype member of the Src family of kinases (SFKs), is over-expressed in various human tumors, and has become a target for anticancer drug design. In this perspective, a series of eighteen 2-pyridone derivatives were synthesized and evaluated for their c-Src kinase inhibitory activity. Among them, eight compounds exhibited c-Src kinase inhibitory activity with IC 50 value of less than 25 μM. Compound 1-[2-(dimethylamino)ethyl]- 5-(2-hydroxy-4-methoxybenzoyl)pyridin-2(1H)-one (36) exhibited the highest c-Src kinase inhibition with an IC50 value of 12.5 μM. Furthermore, the kinase inhibitory activity of compound 36 was studied against EGFR, MAPK and PDK, however no significant activity was observed at the highest tested concentration (300 μM). These results provide insights for further optimization of this scaffold for designing the next generation of 2-pyridone derivatives as candidate Src kinase inhibitors.